Report Company Directory
- OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma by Newsfile Corp.
- OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma by Newsfile Corp.
- OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility by Newsfile Corp.
- OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization by Newsfile Corp.
- OS Therapies to Spinoff OS Animal Health into Standalone Public Company by Newsfile Corp.
- OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update by Newsfile Corp.
- OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma by Newsfile Corp.
- OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma by Newsfile Corp.
- OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma by Newsfile Corp.
- OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting by Newsfile Corp.